The heterogeneous breast cancers can be classified into different subtypes according to their histopathological characteristics and molecular signatures. Foxa1 expression is linked with luminal breast cancer (LBC) with good prognosis, whereas Twist1 expression is associated with basal-like breast cancer (BLBC) with poor prognosis owing to its role in promoting epithelial-to-mesenchymal transition (EMT), invasiveness and metastasis. However, the regulatory and functional relationships between Twist1 and Foxa1 in breast cancer progression are unknown. In this study, we demonstrate that in the estrogen receptor (ERα)-positive LBC cells Twist1 silences Foxa1 expression, which has an essential role in relieving Foxa1-arrested migration, invasion and metastasis of breast cancer cells. Mechanistically, Twist1 binds to Foxa1 proximal promoter and recruits the NuRD transcriptional repressor complex to de-acetylate H3K9 and repress RNA polymerase II recruitment. Twist1 also silences Foxa1 promoter by inhibiting AP-1 recruitment. Twist1 expression in MCF7 cells silenced Foxa1 expression, which was concurrent with the induction of EMT, migration, invasion and metastasis of these cells. Importantly, restored Foxa1 expression in these cells largely inhibited Twist1-promoted migration, invasion and metastasis. Restored Foxa1 expression did not change the Twist1-induced mesenchymal cellular morphology and the expression of Twist1-regulated E-cadherin, β-catenin, vimentin and Slug, but it partially rescued Twist1-silenced ERα and cytokeratin 8 expression and reduced Twist1-induced integrin α5, integrin β1 and MMP9 expression. In a xenografted mouse model, restored Foxa1 also increased Twist1-repressed LBC markers and decreased Twist1-induced BLBC markers. Furthermore, Twist1 expression is negatively correlated with Foxa1 in the human breast tumors. The tumors with high Twist1 and low Foxa1 expressions are associated with poor distant metastasis-free survival. These results demonstrate that Twist1's silencing effect on Foxa1 expression is largely responsible for Twist1-induced migration, invasion and metastasis, but less responsible for Twist1-induced mesenchymal morphogenesis and expression of certain EMT markers.
INTRODUCTION
Molecular profiling studies have classified breast cancers into five subtypes, including luminal A, luminal B, normal-like, HER2positive and basal-like breast cancers (BLBCs). [1] [2] [3] Luminal A tumors have the most favorable prognosis. Luminal B and normal-like tumors have intermediate prognosis. HER2-positive and basal-like tumors are associated with poor relapse-free and overall survivals. [3] [4] [5] [6] Due to the lack of estrogen receptor (ERα) or overexpressed HER2, no targeted therapy is currently available for the BLBC. Although BLBC initially responses to chemotherapy, it usually relapses with drug resistance and thus, represents a major clinical challenge. 7 Therefore, it is important to identify key molecules responsible for BLBC progression and metastasis. Recent studies showed that BLBC possesses an activated epithelial-to-mesenchymal transition (EMT) program and many stem cell-like properties, 8, 9 suggesting transcriptional factors that induce EMT may have critical roles in BLBC progression.
Twist1, a member of the basic helix-loop-helix transcription factor family, is one of the master transcription factors that induce EMT, cell migration and invasion during embryonic development and in cancer cells. [10] [11] [12] Twist1 is expressed in multiple types of invasive cancer cells including some breast cancer cells. 11, 12 Ectopic expression of Twist1 in Twist1-negative breast cancer cells is sufficient to induce EMT and cancer stem-like cell properties. Twist1 expression also enhances cell invasion and metastasis, whereas depletion of Twist1 inhibits cell invasion and metastasis. [12] [13] [14] [15] Twist1 can either silence or activate genes to regulate cancer cell behaviors. 11 We have reported that Twist1 recruits the nucleosome remodeling deacetylase (NuRD) complex to repress E-cadherin and ERα expression to drive EMT, cell invasion and metastasis. 14, 16 Another study also showed that Twist1 recruits DNA methyltransferase 3B to silence ERα expression and contribute to hormone resistance. 17 On the other hand, Twist1 directly upregulates AKT2, Bmi1, Wnt5a, PDGFRα and Jagged1 to promote cancer cell survival, drug resistance, EMT, cancer stem-like cell number, invadopodia formation for extracellular matrix degradation and cancer cell transition into endothelial cells, respectively. 13, [18] [19] [20] [21] [22] In addition, Twist1 overexpression can override oncogene-induced premature senescence by abrogating key regulators of the p53 and Rb-dependent pathways. 23 These studies indicate that Twist1 controls cancer cell behaviors through regulating key genes involved in multiple cellular pathways.
Foxa1 is a forkhead box transcription factor expressed in the mammary luminal epithelial cells. It serves as a pioneer factor by facilitating ERα binding to chromatin and has an important role in maintaining mammary ductal morphology and epithelial differentiation. [24] [25] [26] [27] Foxa1 is also a marker of luminal A breast cancer and is required for many ERα-regulated gene expression and cell proliferation. 24, 25, 28, 29 Foxa1 has been recognized as a determinant of breast tumor response to endocrine therapy and a marker for favorable patient prognosis. 27, 30, 31 Another study showed that Foxa1 silencing allows breast cancer cells to partially shift their transcriptome signatures toward those of BLBC and progress to more aggressive cancer cells. 32 Furthermore, Foxa1 and ERα expressions are decreased during the progression from luminal A to luminal B breast tumors in mice. 33 These studies suggest that silenced Foxa1 expression may facilitate breast cancer progression toward BLBC. However, it remains unknown how Foxa1 expression is silenced during breast cancer progression and how the silenced Foxa1 expression is involved in the BLBCassociated EMT, migration, invasion and metastasis of breast cancer cells.
In this study, we found that Twist1 directly silences Foxa1 expression in breast cancer cells. This silenced Foxa1 expression is largely responsible for Twist1-induced migration, invasion and metastasis of breast cancer cells and for Twist1-repressed luminal breast cancer (LBC) marker gene expression and Twist1-induced BLBC marker gene expression. However, the Twist1-silenced Foxa1 expression is dispensable for Twist1-induced mesenchymal cellular morphogenesis and for the expression of some of the Twist1-induced EMT markers.
RESULTS

Twist1 expression is associated with reduced Foxa1 expression and basal-like human breast tumors
To examine the expressional relationship between Twist1 and Foxa1, we assayed Twist1 and Foxa1 proteins in the luminal and BLBC cell lines. We found Twist1 is only expressed in the three examined BLBC cell lines, including BT549, MDA-MB-436 and SUM1315, and Foxa1 is only expressed in the four examined LBC cell lines, including ZR75-1, BT474, MCF7 and T47D ( Figure 1a ). Analysis of a data set from NCBI GEO database (GSE15361) 34 also revealed that the average expression level of Twist1 mRNA is significantly higher in BLBC cell lines vs LBC cell lines. However, the average expression level of Foxa1 mRNA is markedly reduced in BLBC cell lines vs LBC cell lines. Accordingly, the level of Twist1 expression is negatively correlated with the level of Foxa1 expression in these cell lines (Figures 1b-d) . A similar negative correlation between Twist1 and Foxa1 mRNA expression was also identified from another data set of 281 human breast tumors in NCBI GEO (GSE2034) 35 (Figure 1e ).
To validate the negative correlation at protein levels, we performed immunohistochemistry (IHC) for Twist1 and Foxa1 in a cohort of 276 human breast tumors. Foxa1 and Twist1 proteins were detected in 245 out of 261 (94%) and 13 out of 276 (5%) tumors, respectively, indicating that this cohort mainly consists of luminal breast tumors. Interestingly, 179 out of 261 (68.6%) tumors showed very high (46) Foxa1 immunoreactive scores. However, the 13 Twist1-positive tumors had immunoreactive scores of 6 or lower. Twist1 and Foxa1 immunoreactive scores and ERα, PR and HER2 expression profiles for the 13 Twist1-positive tumors are provided in Supplementary Table S1 . Foxa1 immunoreactivity is significantly reduced in 5 out of the 13 tumors when compared with Twist1-negative tumors ( Figure 1f ). Twist1 protein levels were also negatively correlated with Foxa1 protein levels among these 13 Twist1-positive tumors ( Figure 1g ). Of note, all Twist1-positive tumors are also Foxa1 positive because Twist1 was only detected in a subpopulation of tumor cells. Together, these results demonstrate that the levels of Twist1 expression are negatively correlated with the levels of Foxa1 expression in human breast tumors. Foxa1 expression to promote breast cancer progression. To test this hypothesis, we generated stable MCF7 cell lines with either the empty control vector (MCF7 Ctrl ) or Twist1-expressing vector (MCF7 Twist1 ) from ERα-positive MCF7 LBC cells. We found that Twist1 drastically decreased Foxa1 mRNA and protein in MCF7 Twist1 cells vs MCF7 Ctrl cells (Figure 2a ). Knockdown of Twist1 is known to reduce migration, invasion and metastasis of invasive breast cancer cells. 12, 14, 36, 37 Here, we found that stable knockdown of Twist1 mRNA in SUM1315 and MDA-MB-436 BLBC cells increased Foxa1 mRNA and protein (Figure 2b and Supplementary Figure S1 ). On the other hand, ectopic expression of Foxa1 in either SUM1315 or BT549 breast cancer cells with endogenous Twist1 expression did not alter Twist1 mRNA and protein expression ( Figures 2c and d ), suggesting Foxa1 does not regulate Twist1 expression.
Twist1 binds to Foxa1 promoter and represses its transcription The negative correlation between Twist1 and Foxa1 expression in breast cancer cells and tumors hinted that Twist1 might repress
To determine whether Twist1 directly represses Foxa1 expression, we performed chromatin immunoprecipitation (ChIP) assays to examine whether Twist1 is associated with the enhancer/ promoter regions of the Foxa1 gene. In BT549 cells, we found that Twist1 was associated with the 5′ regulatory region at − 1 kb location from the transcriptional starting site, but it was not associated with the 5′ regulatory regions at − 2, − 3, − 4 and − 5 kb locations ( Figure 3a) . We then constructed and tested a Foxa1 promoter-luciferase (Foxa1-Luc) reporter containing the 1.46-kb 5′ regulatory sequence with the Twist1-binding region (Figure 3b ). Expression of Twist1 significantly decreased the activity of the Foxa1-Luc reporter in MCF7 cells. As demonstrated previously, Twist1 decreased the activity of CDH1-Luc reporter (a positive control), but did not affect the activity of CSF1-Luc reporter (a negative control; Figure 3c ). 14, 38 By contrast, stable knockdown of Twist1 increased the activities of Foxa1 and CDH1 promoter-Luc reporters but did not alter the activity of CSF1-Luc reporter in SUM1315 cells (Supplementary Figure S2a) . These results indicate that Twist1 represses Foxa1 promoter by its direct association with the 5′ regulatory region proximal to Foxa1 promoter.
In silico analysis of the proximal Foxa1 promoter region revealed 11 E-boxes. Twist1 is more likely to bind two (EB3 and EB7) of these E-boxes as predicted by MatInspector Software (Genomatix; Figure 3b ). Deletion of either EB3 in Foxa1-Luc (EB3M-Luc) reporter or EB7 in Foxa1-Luc (EB7M-Luc) reporter significantly relieved Twist1-repressed Foxa1 promoter activity in MCF7 cells. Deletions of both EB3 and EB7 in Foxa1-Luc (EB3/7M-Luc) reporter additively relieved Twist1-repressed Foxa1 promoter activity (Figures 3b and d) . In SUM1315 cells with endogenous Twist1 expression, mutation of EB3 and/or EB7 increased Foxa1-Luc reporter activity, whereas knockdown of Twist1 resulted in lesser fold increases in the mutant Foxa1 promoter activities vs the wild-type promoter (Supplementary Figure S2b ). These results demonstrate that Twist1 can use both EB3 and EB7 sites to silence the transcriptional activity of Foxa1 promoter. Although the activity of EB3/7M-Luc reporter was still partially silenced by Twist1 in MCF7 cells, Twist1 might also bind to other E-boxes to repress Foxa1 promoter.
Twist1 recruits NuRD complex to Foxa1 promoter and deacetylates H3K9 We reported that Twist1 recruits NuRD complex to repress CDH1 and ERα promoters. 14, 16 Here, our ChIP assays revealed that Twist1 was recruited to the proximal promoter regions of both CDH1 and Foxa1 genes in MCF7 Twist1 cells (Figure 3e ). The endogenous HDAC2 and MTA2 proteins, two of the NuRD complex components, were also recruited to the Twist1-binding regions of both CDH1 and Foxa1 genes in a Twist1 expression-dependent manner (Figures 3f and g) . In agreement with the Twist1-recruited NuRD complex containing histone deacetylase, the levels of acetylated histone H3K9 (H3K9-ace) were markedly reduced in the same Twist1-binding regions of both CDH1 and Foxa1 genes in MCF7 Twist1 cells vs MCF7 Ctrl cells ( Figure 3h ). Accordingly, RNA polymerase II recruited to these gene promoters was significantly reduced in MCF7 Twist1 cells vs MCF7 Ctrl cells (Figure 3i ). Furthermore, knockdown of Twist1 in SUM1315 cells decreased HDAC2 and MTA2 recruitments and increased H3K9-ace and RNA polymerase II recruitment on Foxa1 promoter (Supplementary Figure S3 ). These results demonstrate that Twist1 strongly silences the transcriptional activity of the Foxa1 promoter by recruiting the NuRD gene-repressing complex. Overexpression of Foxa1 did not influence Twist1 mRNA and protein in both BT549 and SUM1315 cells. All experiments were repeated three times and the representative data are presented. *P o0.05 by Student's t-test between the control and testing groups.
Twist1 silences Foxa1 expression through inhibiting AP-1-promoted activation of the Foxa1 promoter Analysis of the Foxa1 promoter region identified two AP-1 sites conserved in both human and mouse Foxa1 genes ( Figure 4a ). We found that in MCF7 cells overexpressed c-Jun and c-Fos significantly increased the activity of Foxa1-Luc reporter in a dose-dependent manner, whereas knockdown of c-Fos drastically reduced both Foxa1 mRNA and protein expression ( Figures 4b and  c ). This c-Fos-activated Foxa1 expression should be independent of Twist1, because Twist1 protein was undetectable in MCF7 cells with and without c-Fos knockdown (data not shown) and the lowlevel Twist1 mRNA was not altered in MCF7 cells with c-Fos knockdown (Supplementary Figure S4 ). Furthermore, deletion of either AP-1 site at bp − 895 or bp − 798 or both diminished AP-1promoted activities of the Foxa1 AP1M1-Luc, AP1M2-Luc and AP1M1/2-Luc reporters (Figure 4d ). These results demonstrate that AP-1 is an essential transcriptional activator of Foxa1 promoter. ChIP assays revealed that Twist1 expression in MCF7 cells abolished c-Fos recruitment to Foxa1 promoter (Figure 4e ), whereas knockdown of Twist1 in SUM1315 cells increased c-Fos recruitment to Foxa1 promoter (Supplementary Figure S5a) . As a control, Twist1 did not inhibit c-Fos recruitment to CSF1 promoter ( Figure 4e ). 38 Mutation of the AP-1 sites in Foxa1 promoter, which simulates Twist1-prevented AP-1 binding, drastically reduced the basal activity of Foxa1 promoter. Thus, Twist1 expression was unable to further reduce the little activities of these mutant promoters as it did to the wild-type promoter (Figure 4f ). Consistent results were also observed in SUM1315 cells with Twist1 knockdown (Supplementary Figure S5b) . These results suggest that silencing AP-1-mediated activation of Foxa1 promoter is an important mechanism for Twist1-repressed Foxa1 expression.
Twist1-silenced Foxa1 expression is not responsible for Twist1induced cell morphological change but it mediates the expression of some Twist1-regulated genes To examine whether Twist1-silenced Foxa1 expression is responsible for Twist1-induced morphology and gene expression changes in breast cancer cells, we stably restored Foxa1 expression in MCF7 Twist1 cell lines (designated as MCF7 Twist1+Foxa1 cell lines) with Twist1-silenced Foxa1 expression ( Figure 5a ). As expected, MCF7 Ctrl cells showed epithelial tumor cell morphology identical to their parent MCF7 cells, whereas MCF7 Twist1 cells had an elongated spindle shape consistent with their EMT phenotype. MCF7 Twist1+Foxa1 cells with restored Foxa1 expression showed a cellular morphology very similar to MCF7 Twist1 cells (Figure 5b) ,
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Luc. Activity (Figure 5c ). Moreover, Twist1 strongly induced vimentin, integrin β1, integrin α5 and MMP9 expression, but did not change fibronectin expression in MCF7 Twist1 cells as compared with MCF7 Ctrl cells. Restored Foxa1 expression had no effect on vimentin expression, but inhibited Twist1-induced integrin β1, integrin α5 and MMP9 expression, and slightly increased fibronectin in MCF7 Twist1+Foxa1 cells as compared with MCF7 Twist1 cells (Figures 5c-f and data not shown). In addition, Slug (Snail2) expression was increased in MCF7 Twist1 cells vs MCF7 Ctrl cells, but restored Foxa1 expression did not affect Twist1-induced Slug expression in MCF7 Twist1+Foxa1 cells vs MCF7 Twist1 cells. The expression levels of Snail1, Zeb1 and Zeb2 mRNAs were very low and remained unchanged in MCF7 Ctrl , MCF7 Twist1 and MCF7 Twist1+Foxa1 cells (data not shown). These results suggest that silenced Foxa1 is not responsible for Twist1induced mesenchymal cell morphology and most EMT marker gene expression, but responsible for permitting the expression of ERα, K8 and other selective Twist1-regulated genes related to cell migration and invasion such as integrin β1, integrin α5 and MMP9.
Silencing Foxa1 expression is required for Twist1 to promote migration, invasion and metastasis in breast cancer cells Expression of Foxa1 alone showed no effects on MCF7 cell migration and invasion. However, restored Foxa1 expression in MCF7 Twist1+Foxa1 cells significantly suppressed Twist1-induced cell migration on the culture plate and invasion through a Matrigel layer (Figures 6a and b ). To examine whether Foxa1 could inhibit Twist1-promoted metastasis in vivo, we injected MCF7 Ctrl , MCF7 Foxa1 , MCF7 Twist1 and MCF7 Twist1+Foxa1 cells into the tail veins of SCID mice. After 4 weeks, we found metastatic tumor foci in 20% (1/5), 0% (0/5), 100% (5/5) and 20% (1/5) of lungs in mice received MCF7 Ctrl , MCF7 Foxa1 , MCF7 Twist1 and MCF7 Twist1+Foxa1 cells, respectively (Figure 6c ). The average number of metastasis foci developed in each lung was significantly increased in MCF7 Twist1 group vs MCF7 Ctrl , MCF7 Foxa1 or MCF7 Twist1+Foxa1 group (Figure 6d) . Accordingly, the lung metastasis index reflecting the percentage of tumor area to lung tissue area was 425-fold higher in the recipient mice of MCF7 Twist1 cells vs the recipient mice of MCF7 Ctrl , MCF7 Foxa1 or MCF7 Twist1+Foxa1 cells (Figure 6e ). To examine if Figure S6a) . Again, Twist1promoted MCF7 Twist1 tumor metastasis, whereas restored Foxa1 inhibited MCF7 Twist1+Foxa1 tumor metastasis in SCID mice (Supplementary Figure S6b and c) . Together, these results demonstrate that Twist1-repressed Foxa1 expression may be important for BLBC progression and is required for Twist1promoted migration, invasion and metastasis of breast cancer cells.
Breast tumor patients with high Twist1 and low Foxa1 expression exhibit poor distant metastasis-free survival To assess the clinical relevance of the Twist1-Foxa1 regulatory axis in human breast cancer progression, we analyzed the association between the expression levels of Twist1 and Foxa1 and the clinical outcomes in a large breast cancer cohort with distant metastasisfree survival (DMFS) data. 39 All patients were divided into four groups according to the median Twist1 and Foxa1 expression.
The Twist1 High /Foxa1 Low subgroup exhibited significantly worse DMFS than the Twist1 Low /Foxa1 High and the Twist1 High /Foxa1 High subgroups (Figure 7a ). Interestingly, when the cohort was further subgrouped into luminal A, luminal B, HER2-positive and basal-like subtypes, only the Twist1 High /Foxa1 Low patients with luminal A tumors exhibited significantly worse DMFS as compared with Twist1 Low /Foxa1 High and Twist1 High /Foxa1 High patients with luminal A tumors (Supplementary Figure S7 ). Further analyses revealed that the percentages of Twist1 Low Foxa1 High and Twist1 High Foxa1 High subgroup tumors in luminal A and luminal B subtypes are much higher than those in Basal-like and HER2positive subtypes, whereas the percentages of Twist1 Low /Foxa1 Low and Twist1 high /Foxa1 Low tumors in luminal A and luminal B subtypes are much lower than those in the more aggressive basallike and HER2-positive subtypes (Figure 7b ). Moreover, Fisher's exact test revealed that Twist1 High tumors are significantly associated with Foxa1 Low tumors, whereas tumors with Twist1 Low tumors are associated with Foxa1 High tumors (Figure 7c ), indicating a negative correlation between Twist1 and Foxa1 expression profiles. These results suggest that Twist1-mediated repression of Foxa1 expression has an important role in breast cancer metastasis and Foxa1 can effectively inhibit metastasis in tumors with high expression of both Twist1 and Foxa1. Twist1 silences Foxa1 to promote invasion and metastasis Y Xu et al drive cell invasiveness and metastasis. However, the regulatory and functional relationship between Twist1 and Foxa1 in breast cancer progression remains unknown. In this study, we found Twist1 expression negatively correlates with Foxa1 expression in human breast cancer cells and tumors. Mechanistically, Twist1 directly associates with Foxa1 promoter to recruit NuRD complex and prevent AP-1 binding to Foxa1 promoter, resulting in decreased H3K9 acetylation, reduced RNA polymerase II recruitment and silenced Foxa1 expression. It is conceivable that constitutive AP-1 binding in LBC cells with no Twist1 has a major role to maintain a high level of Foxa1 expression and thus a luminal phenotype. Twist1 expression in partial or full EMT breast cancer cells may partially or fully inhibit AP-1 recruitment to Foxa1 promoter through NuRD complex-mediated changes in histone codes and thus reduce or silence Foxa1 expression, causing breast cancer progression toward BLBC. Therefore, our findings indicate that Foxa1 is a direct target of Twist1 during breast cancer progression and thus provide a possible new mechanism for the loss of Foxa1 during breast cancer progression from a luminal ERαpositive subtype to an ERα-negative BLBC subtype.
DISCUSSION
In agreement with the established function of Twist1, 11 ectopic expression of Twist1 in MCF7 cells induced a mesenchymal morphology and gene expression signature, but decreased epithelial gene expression. Using this cellular model, we addressed how much the Twist1-silenced Foxa1 expression contributes to Twist1-induced mesenchymal morphogenesis and gene expression in breast cancer cells by restoring Foxa1 in Twist1-expressing MCF7 cells. Interestingly, though previous studies have shown Foxa1 represses EMT-linked mesenchymal morphogenesis in pancreatic cancer cells, 40 we found that restored Foxa1 did not change the mesenchymal cell morphology induced by Twist1 in MCF7 Twist1+Foxa1 cells. In agreement with this, restored Foxa1 did not rescue the expression levels of some Twist1-repressed epithelial genes such as E-cadherin and β-catenin and also did not repress the expression of some Twist1-induced mesenchymal genes such as vimentin and Slug. We can also estimate the role of Foxa1 silencing in EMT by comparing the genes regulated by Foxa1 in the LBC cells with the previously published EMT signature genes. 32, 41 Among the 1118 Foxa1-regulated genes, 32 we only found ARHGAP8, LMCD1, NMU, PPAP2B, PRKCH and SLPI in the 251 EMT signature gene list. 41 None of these six genes has been shown to regulate the mesenchymal morphogenesis of breast cancer cells. Together, these findings suggest that Twist1-silenced Foxa1 expression is not a major regulatory pathway for the mesenchymal morphogenesis and for the expression of most typical EMT signature genes in breast cancer cells. Interestingly, restored Foxa1 does partially rescue ERα and K8 expression and strongly downregulate Twist1-induced integrin β1, integrin α5 and MMP9 expression. Because ERα and K8 are markers of the LBC and integrins β1 and α5 are preferentially expressed in BLBC, it is conceivable that Twist1-silenced Foxa1 expression has a crucial role in promoting BLBC progression. Foxa1 could either directly or indirectly regulate these genes. It has been reported that Foxa1 upregulates but Twist1 directly represses ERα expression. 16, 17, 26 The results of the present study suggest that both the loss of Foxa1-mediated activation due to Twist1-silenced Foxa1 expression and the Twist1-mediated active repression are required for shutting down ERα expression and developing endocrine resistance during breast cancer progression toward BLBC. These interpretations are consistent with the previous studies showing that Foxa1 expression is associated with good responses to endocrine therapy and the loss of Foxa1 is associated with BLBC progression. 24, 25, [27] [28] [29] [30] [31] [32] More importantly, restored Foxa1 robustly inhibited Twist1-promoted migration, invasion and metastasis. These could be partially attributed to the downregulation of Twist1-induced expression of MMP9 and integrins β1 and 5α, since these proteins are known to promote cell invasiveness and metastasis. [42] [43] [44] [45] [46] [47] In addition, we demonstrate that Twist1 expressed in MCF7 cells increased most BLBC markers but decreased most LBC markers in these cell-derived xenograft tumors, whereas restored Foxa1 in Twist1-expressing MCF7 cells decreased many BLBC markers but increased many LBC markers. These results further support the notion that Twist1-repressed Foxa1 expression may have an important role to promote BLBC progression.
In previous studies, the role of Twist1 in promoting metastasis was largely attributed to its capability to induce EMT and enhance cancer stem cell features. [11] [12] [13] 48 Now, the consensus from present and previous studies suggests that Twist1 may serve as a master regulator in breast cancer progression by regulating multiple genes involved in multiple pathways. On one hand, Twist1 may regulate one subgroup of genes, such as downregulating E-cadherin and ERα 14, 16, 17 and upregulating Bmi1, AKT2, Wnt5a and vimentin [18] [19] [20] to promote EMT, cancer stem cell features, cell migration, invasion and metastasis. On the other hand, Twist1 may regulate another subgroup of genes, such as upregulating PDGFRα to induce invadopodia formation for cell invasion 21 and downregulating Foxa1 to decrease ERα, CK8 and other LBC markers and increase integrin α 5 , integrin β1, MMP9 and other BLBC markers for promoting BLBC progression and breast cancer cell migration, invasion and metastasis. Although these multiple Twist1-regulated genes and pathways may not be equally important, they may work cooperatively to drive breast cancer progression and metastasis. A single targeting event such as silencing Foxa1 or upregulating AKT2 can be required but may not be sufficient for Twist1-promoted migration, invasion and metastasis of breast cancer cells.
Analysis of a large cohort data set showed that tumors with Twist1 High Foxa1 Low expression are associated with worse DMFS vs Twist1 Low Foxa1 High and Twist1 High Foxa1 High tumors, which supports the notion that Twist1-silenced Foxa1 expression can promote breast cancer metastasis. Interestingly, this association is only observed in the mixed subtypes and luminal A subgroup, but not in the luminal B, HER2-positive or basal-like subgroups. We noticed that the tumor numbers with each expression profile are more evenly distributed in the luminal A and luminal B subgroups vs basal-like and HER2-positive subgroups. The later two subtypes contain too few tumors with Twist1 Low Foxa1 High and Twist1 High Foxa1 High expressions and thus do not support a valid statistical analysis to compare Twist1 Low Foxa1 High or Twist1 High Foxa1 High tumors with Twist1 Low Foxa1 Low or Twist1 High Foxa1 Low tumors. Nevertheless, the facts that Twist1 is expressed at high levels in 440% of basal-like and HER2-positive tumors and Foxa1 is expressed at low levels in 96% of basal-like and 77% of HER2positive tumors also support the notion that silenced Foxa1 expression is associated with more malignant breast cancer subtypes. For the luminal B subtype group, other factors in addition to Twist1 and Foxa1 may determine DMFS of these patients.
Analysis of tumor tissue microarrays by IHC also revealed an overall negative correlation between Twist1 and Foxa1 proteins. However, we did not find many Twist1-positive tumors from the examined breast tumor microarrays either because of not many BLBCs in the cohort or missed identification of some positive tumors due to the small area of tissue microarrays insufficient to cover heterogeneous regions for Twist1 expression in a tumor. IHC revealed that Twist1 is usually expressed only in a small subpopulation of tumor cells or a small region in a tumor. Most of these Twist1-positive tumors also contain many Foxa1-positive luminal tumor cells. These double-positive tumors may contain Twist1-positive/Foxa1-positive, Twist1-positive/Foxa1-negative and/or Twist1-negative/Foxa1-positive cells. These observations support the notion that Twist1 expressed in a subset of breast tumor cells represses Foxa1 expression and drive EMT to promote BLBC progression from this subset of tumor cells.
In summary, we found that Twist1 directly represses the transcriptional activity of the Foxa1 promoter in breast cancer cells. Twist1-silenced Foxa1 expression is largely responsible for Twist1-mediated migration, invasion and metastasis, but less responsible for Twist1-induced EMT morphology and some EMT marker expression of breast cancer cells. Therefore, maintenance or restoration of Foxa1 expression and function in Twist1expressing breast cancer cells may be an effective approach to inhibit Twist1-promoted breast cancer cell migration, invasion and metastasis as well as BLBC progression.
MATERIALS AND METHODS
Cell culture HEK293T, MCF7, BT474 and ZR75-1 cells were obtained from ATCC and cultured in DMEM medium containing 10% of fetal bovine serum. T47D and BT549 cells were obtained from ATCC and cultured in RPMI-1640 medium with 10% of fetal bovine serum. SUM1315 cells were cultured in Hyclone Nutrient Mixture with 5% of fetal bovine serum, 5 μg/ml of insulin and 10 ng/ml of epidermal growth factor. All cells were cultured at 37°C in a tissue culture incubator supplied with 5% CO 2 .
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Western blotting
Western blotting was carried out as described previously. 49 Table S2 ). The measurement of 18S or β-actin mRNA was used as an endogenous normalizer.
Plasmids and cell transfection
The 1.5 kb human Foxa1 proximal promoter was amplified by PCR using specific primers ( Supplementary Table S2 ) from the gemomic DNA of MCF7 cells and subcloned into pGL3-basic-luciferase plasmid to get Foxa1-Luc plasmid. The human E-cadherin-Luc and CSF1-Luc plasmids were described previously. 14, 38 The pCDNA-Twist1-2 × flag expression plasmid was constructed by subcloning human Twist1 cDNA into the pCDNA-2 × flag plasmid. The pCDH-Foxa1 plasmid was a gift from Dr Bin He at Baylor College of Medicine. For promoter-reporter assay, MCF7 cells were transfected with the expression vectors and promoter-luciferase reporter plasmid using the polyethylenimine reagent (23966-2, Polyscience, Niles, IL, USA). 52 The transfected cells were harvested 24 h and lysed with the Reporter Lysis buffer (Promega, Madison, WI, USA) for luciferase assay as described. 38 The relative luciferase activity was normalized to the total amount of protein assayed.
To generate MCF7 Twist1 cell lines, MCF7 cells were transfected with pCDNA-2 × flag and pCDNA-Twist1-2 × flag plasmids using the Polyethylenimine reagent. Transfected cells were cultured in DMEM medium containing 2 μg/ml of Hygromycin for 2 weeks. To generate MCF7 Twist1+Foxa1 cell lines, two MCF7 Twist1 cell lines were transfected with pCDH-Foxa1 plasmid and growth-selected for 14 days with 4 μg/ml of Puromycin.
In siRNA-based knocking-down experiments, non-targeting control siRNAs and siRNAs were purchased from Dharmacon (Lafayette, CO, USA) and transfected using the HiPerFect Transfection Reagent (301705, QIAGEN, Valencia, CA, USA).
ChIP assay
The DNA-bound proteins were cross-linked using 1% formaldehyde for 10 min. ChIP assays were performed as described previously. 14, 38 Antibodies used in these ChIP assays were for Twist1 (ab50887), c-Jun (ab31419, Abcam), MTA2 (28791), HDAC2 (7899x, Santa Cruz, Dallas, TX, USA), c-Fos (2250, Cell Signaling), Histone H3K9ac (39585, Active motif, Carlsbad, CA, USA), RNA pol II (PLA0127, Sigma-Aldrich) and M2 Flag antibody beads (A2220, Sigma-Aldrich). ChIP-grade mouse IgG and rabbit IgG (Abcam) were used as negative controls. The sequences of PCR primers used for amplifying the precipitated DNA samples are listed in Supplementary Table S2 .
Cell migration and invasion assays
Cell migration and invasion capabilities were measured as described previously. 53 Briefly, individual cell migration was directly traced in a 96well plate for 18 h using the Cell Motility HCS Reagent kit (K08-000-11, Thermo Scientific, Rockford, IL, USA). The track areas on the electronic images were quantitatively measured using the Image J software (Bethesda, MI, USA). Cell invasion was assayed by using BioCoat Matrigel Invasion Chambers (BD Biosciences) according to the manufactures instruction.
Metastasis assay
Animal protocols were approved by IACUC at Baylor College of Medicine. MCF7 Ctrl , MCF7 Foxa1 , MCF7 Twist1 or MCF7 Twist1+Foxa1 cells (1 × 10 6 ) were injected into the tail vein of each 8-week-old female SCID mouse. Mice were randomly grouped with five mice in each group. This sample size was estimated to have adequate statistical power. These mice were killed in 4 weeks after the injection according to the NIH guidelines. The investigator was blinded to the group allocation during experiment. Mouse lung tissues were collected, photographed and processed for paraffin section. Metastasis was evaluated by counting the visible metastatic foci and measuring metastasis tumor area vs the lung area on H&E-stained lung sections as described previously. 54, 55 Statistical analyses All data were collected from several independent experiments to ensure adequate power (480%). Each assay was performed in triplicate whenever applicable. All data were expressed as mean ± s.e.m. Prism 4 Software (GraphPad, La Jolla, CA, USA) was used to perform two-sided Student's t-test to analyze the data sets of mRNA level, tumor volume, luciferase activity, cell migration and invasion, metastatic tumor number and index, which are normal-distributed. Log-rank test was used to analyze the data sets of mice tumor-free survival and human breast cancer patient DMFS. Fisher's exact test was used to analyze the data sets of Foxa1 IHC scores and patient distribution in cohort. Pearson's Correlation test was used to analyze the Twist1 and Foxa1 expression data sets. In all statistical analyses, Po0.05 was considered significant.
